BioGaia acquires its US distributor – strengthening its market position in the US
BioGaia AB (publ) has, through its US subsidiary BioGaia Biologics Inc, signed an agreement to acquire all shares in Nutraceutics...
Read moreMerry Christmas and a Happy New Year
BioGaia wishes you a Merry Christmas and a Healthy and Happy New Year!...
Read moreBioGaia AB’s Nomination Committee for the 2022 Annual General Meeting
BioGaia AB’s Nomination Committee for the Annual General Meeting 2022 has been appointed based on the ownership structure as...
Read moreBioGaia AB Interim Management Statement – January – September 2021
Third quarter 2021 · Net sales amounted to SEK 173.8 million (132.0), an increase of 32% (excluding foreign exchange...
Read moreBioGaia starts its own distribution in the UK
Beginning in November 2021, BioGaia will be selling its probiotic products under its own management in the UK market. The...
Read moreBioGaia Pharma secures approval for two clinical trials for its pharmaceutical candidates
BioGaia Pharma has received formal approval from relevant authorities to proceed with both of its planned clinical trials. The trials...
Read moreBioGaia research wins first prize at LAB Symposium
The prestigious International Symposium on Lactic Acid Bacteria was held between 23–25 August and gathered more than 300 participants....
Read moreBioGaia Interim report January – June 2021
Second quarter 2021 · Net sales amounted to SEK 203.1 million (244.7), a decrease of 17% (excluding foreign exchange...
Read more